Category | Criteria |
---|---|
Population(s) | Individuals with dementia and BPSD living in the community, long term care, or in specialized longer stay settings |
Intervention | All anticonvulsants for BPSD including valproic acid, gabapentin, pregabalin, carbamazepine, phenytoin, topiramate, levetiracetam, zonisamide, oxcarbazepine, lamotrigine, and phenobarbital. Benzodiazepines excluded |
Control | Placebo, no intervention, or other active treatments including both non-pharmacologic or pharmacologic treatments |
Outcomes | Primary outcomes: We will consider studies that use validated measures of BPSD such as |
 1. Neuropsychiatric Inventory [19]. | |
 2. Cohen-Mansfield Agitation Inventory [20] | |
 3. Brief Psychiatric Rating Scale [21] | |
 4. Clinical Global Impression Scale | |
Secondary outcomes: | |
 1. Caregiver burden and quality of life | |
 2. Placement in long term care facility from home. | |
 3. Serious adverse effects | |
 4. Treatment discontinuation due to serious adverse effects | |
Study design | Randomized control trials and crossover trials. |
Timing | Any duration of follow-up longer than 2 weeks. |